Dystrophin is a tumor suppressor in human cancers with myogenic programs

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• Myogenic differentiation is common in human mesenchymal tumors like GIST, RMS, and LMS.
• The dystrophin gene (DMD) is associated with muscular dystrophies and encodes dystrophin protein.

Purpose of the Study:

• To investigate the role of dystrophin gene (DMD) deletions in the progression of myogenic tumors to high-grade sarcomas.
• To determine if dystrophin functions as a tumor suppressor and anti-metastatic factor in these cancers.

Main Methods:

• Analysis of DMD gene deletions in human tumor samples (GIST, RMS, LMS).
• Assessment of dystrophin isoform expression in neoplastic and benign tumor counterparts.
• In vitro assays evaluating dystrophin's effect on sarcoma cell migration, invasion, anchorage independence, and invadopodia formation.

Main Results:

• Intragenic DMD deletions were identified as a frequent mechanism in high-grade sarcoma progression.
• DMD deletions inactivate large dystrophin isoforms while preserving essential smaller ones.
• Dystrophin expression was significantly reduced or absent in metastatic GIST (96%), embryonal RMS (100%), and LMS (62%).
• Dystrophin was found to inhibit sarcoma cell migration, invasion, anchorage independence, and invadopodia formation.

Conclusions:

• Dystrophin acts as a tumor suppressor and anti-metastatic factor in myogenic sarcomas.
• DMD gene deletions are critical for the progression of these tumors to lethal stages.
• Therapies targeting muscular dystrophies may offer novel treatment strategies for advanced sarcomas.